Meng Chao, Tang Chuanhao, Liang Jun
Department of Oncology, Peking University International Hospital, Beijing 102206, China.
Zhongguo Fei Ai Za Zhi. 2018 Aug 20;21(8):615-619. doi: 10.3779/j.issn.1009-3419.2018.08.07.
Bone is one of the most metastatic sites of advanced malignant tumors. With the continuous improvement of diagnosis and treatment of malignant tumors, the survival time of patients is prolonged and incidence of bone metastases also increases. Lung cancer is the leading cause of cancer-related mortality worldwide. It is estimated that the incidence of bone metastases in patients advanced lung cancer is about 30%-40%. The traditional diagnosis of bone metastases in lung cancer is based on clinical symptoms, X ray, computed tomography (CT), magnetic resonance imaging (MRI) and pathology. Recently, a large number of exploratory studies have reported blood biomarkers as indicators of bone metastasis screening and efficacy evaluation. In this review, we summarize the progress of biomarkers in diagnosis of bone metastases of lung cancer. .
骨是晚期恶性肿瘤最常见的转移部位之一。随着恶性肿瘤诊疗水平的不断提高，患者生存时间延长，骨转移的发生率也随之增加。肺癌是全球癌症相关死亡的主要原因。据估计，晚期肺癌患者发生骨转移的几率约为30%-40%。肺癌骨转移的传统诊断基于临床症状、X线、计算机断层扫描（CT）、磁共振成像（MRI）及病理检查。近年来，大量探索性研究报道了血液生物标志物可作为骨转移筛查及疗效评估的指标。在本综述中，我们总结了生物标志物在肺癌骨转移诊断中的研究进展。
